A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

By A. Sniderman, K. Williams, J. Contois, Howard M. Monroe, M. McQueen, J. de Graaf, C. Furberg. Circulation. Cardiovascular Quality and Outcomes, 2011

636 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/75457cea9f039433bcf2a72a02dc8b74a38fcda1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. I. Graham
2. George Davey Smith
3. Michael Holmes
4. P. Ridker
5. L. Melvin
6. Peter Libby

In Endocrinology, Diabetes and Metabolism

1. I. Graham
2. George Davey Smith
3. Michael Holmes
4. P. Ridker
5. Peter Libby

In Surgery

1. I. Graham
2. P. Ridker
3. George Davey Smith
4. Michael Holmes
5. Aeilko H. Zwinderman
6. Peter Libby
7. L. Melvin

Citations in the corpus

• Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. (2012, result): “This meta-analysis concluded that apoB was superior to non–HDL-C and that both were superior to LDL-C as a predictor of cardiovascular risk.(27) In contrast to the extensive literature on the predictive value of lipids and apolipoproteins in population studies, the body of evidence on statintreated ”
• Dyslipidemia in Obesity: Mechanisms and Potential Targets (2013, background): “apo B as treatment target over LDL-C would prevent an additional 300,000–500,000 cardiovascular events in the US population over a 10-year period [139].”
• Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis (2020, background): “From the perspective of which trait has the strongest association with cardiovascular risk, meta-analyses have identified that apolipoprotein B has a comparatively higher relative risk than that derived from LDL cholesterol [19].”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, result): “In contrast, in another meta-analysis of LDL-C, non-HDL-C and apoB, the latter was superior as a marker of CV risk.(103) ApoB can be used as a secondary target, as suggested for non-HDL-C, when analysis for apoB is available.”